Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BLCO 
Bausch + Lomb Corp (BLCO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/03/2025: BLCO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
15 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $17.1
1 Year Target Price $17.1
| 3 | Strong Buy |
| 3 | Buy |
| 8 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -14.11% | Avg. Invested days 49 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/03/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 6.01B USD | Price to earnings Ratio - | 1Y Target Price 17.1 |
Price to earnings Ratio - | 1Y Target Price 17.1 | ||
Volume (30-day avg) 15 | Beta 0.63 | 52 Weeks Range 10.45 - 20.71 | Updated Date 12/3/2025 |
52 Weeks Range 10.45 - 20.71 | Updated Date 12/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.85 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -6.13% | Operating Margin (TTM) 6.25% |
Management Effectiveness
Return on Assets (TTM) 0.53% | Return on Equity (TTM) -4.5% |
Valuation
Trailing PE - | Forward PE 16.95 | Enterprise Value 10685968505 | Price to Sales(TTM) 1.21 |
Enterprise Value 10685968505 | Price to Sales(TTM) 1.21 | ||
Enterprise Value to Revenue 2.15 | Enterprise Value to EBITDA 20.99 | Shares Outstanding 354189784 | Shares Floating 42456729 |
Shares Outstanding 354189784 | Shares Floating 42456729 | ||
Percent Insiders 89.01 | Percent Institutions 11.29 |
Upturn AI SWOT
Bausch + Lomb Corp
Company Overview
History and Background
Bausch + Lomb was founded in 1853 in Rochester, New York, by John Jacob Bausch and Henry Lomb. Initially a small optical goods shop, it evolved into a global eye health company through innovations in contact lenses, lens care products, and ophthalmic surgical devices.
Core Business Areas
- Vision Care: Includes contact lenses (daily disposables, multifocal, toric), lens care products (solutions, drops), and related accessories. This is B+L's largest segment.
- Ophthalmic Pharmaceuticals: Focuses on prescription medications for eye diseases, including glaucoma, dry eye, and allergies.
- Surgical: Develops and markets surgical equipment, instruments, and consumables for cataract, refractive, and vitreoretinal surgery.
Leadership and Structure
The CEO of Bausch + Lomb is Brent Saunders. The company operates with a divisional structure aligned with its core business areas. It is publicly traded (BLCO). Bausch Health Companies Inc. was the parent company prior to the IPO of Bausch + Lomb.
Top Products and Market Share
Key Offerings
- Biotrue ONEday: A leading daily disposable contact lens. Competitors include Alcon's Dailies and Johnson & Johnson's Acuvue. Market share is estimated to be in the top 3 of Daily Disposable lenses, but specific data requires subscription to market research.
- Market Share (%):
- Market Share (%):
- ULTRA: A monthly contact lens for digital device users. Competitors include CooperVision's Biofinity and Alcon's Air Optix. Market share is estimated to be in the top 3 of Monthly lenses, but specific data requires subscription to market research.
- Lumify: An over-the-counter eye drop for redness relief. Competitors include Visine and Clear Eyes. Lumify has captured a significant share of the OTC redness relief market. Market share is estimated to be in the top 1 or 2 of OTC redness relief, but specific data requires subscription to market research.
- Market Share (%):
Market Dynamics
Industry Overview
The eye health industry is driven by an aging population, increasing prevalence of eye diseases (e.g., cataracts, glaucoma, dry eye), and growing adoption of contact lenses. Technological advancements in lens materials and surgical techniques are also fueling market growth.
Positioning
Bausch + Lomb is a global leader in eye health, with a strong brand reputation, diversified product portfolio, and extensive distribution network. The company benefits from its history of innovation and strong relationships with eye care professionals.
Total Addressable Market (TAM)
The global ophthalmic market is expected to reach hundreds of billions of USD in the coming years. Bausch + Lomb is well-positioned to capture a significant share of this market due to its broad product portfolio and global presence.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Diversified product portfolio
- Global presence and distribution network
- Established relationships with eye care professionals
- History of innovation
Weaknesses
- High debt levels (related to its spin-off from Bausch Health)
- Competition from larger, more diversified healthcare companies
- Exposure to regulatory risks
- Dependence on key products
Opportunities
- Growth in emerging markets
- Development of new products and technologies
- Expansion into adjacent market segments
- Strategic acquisitions and partnerships
- Increasing demand for vision correction and eye care solutions
Threats
- Intense competition
- Pricing pressures
- Generic erosion
- Economic downturns
- Changes in healthcare regulations
Competitors and Market Share
Key Competitors
- ALC (Alcon)
- JNJ (Johnson & Johnson)
- COO (CooperCompanies)
Competitive Landscape
Bausch + Lomb competes with other large eye health companies like Alcon and Johnson & Johnson. B+L has a long history and broad product portfolio, but is smaller and less diversified than some of its competitors. Its focus on eye health can be an advantage, but it also makes it more vulnerable to changes in the eye care market.
Major Acquisitions
XIIDRA
- Year: 2023
- Acquisition Price (USD millions): 2500
- Strategic Rationale: Adds a key dry-eye treatment option, expanding Bausch + Lomb's pharmaceutical portfolio and market presence. The deal includes up to $1.75 billion in contingent payments.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the recent IPO. Bausch + Lomb's past performance as part of Bausch Health is not directly indicative of its future performance as an independent company.
Future Projections: Analyst estimates vary, but generally anticipate growth driven by new product launches, expansion in emerging markets, and increasing demand for eye care solutions.
Recent Initiatives: Recent initiatives include investing in R&D, launching new products, and expanding its presence in key markets.
Summary
Bausch + Lomb is a storied company with a broad portfolio in the growing eye health market. While its recent spin-off presents challenges like debt, it also offers focused growth opportunities. The company's strong brand and distribution network are assets, but competition and regulatory risks must be carefully managed. The recent Xiidra acquisition should boost their pharmaceutical market share.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports
- Public News Sources
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market share data is approximate. Financial data needs to be taken from recent reporting from the company. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bausch + Lomb Corp
Exchange NYSE | Headquaters Vaughan, ON, Canada | ||
IPO Launch date 2022-05-06 | CEO & Chairman Mr. Brenton L. Saunders J.D. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 13500 | Website https://www.bausch.com |
Full time employees 13500 | Website https://www.bausch.com | ||
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provides optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.